<DOC>
	<DOCNO>NCT00919451</DOCNO>
	<brief_summary>Study 1B : Ciclosporin management steroid resistant Type 1 Reactions Leprosy Objective : A pilot study assess efficacy safety Ciclosporin second -line drug patient Type 1 Reactions respond 12 week course Prednisolone .</brief_summary>
	<brief_title>Ciclosporin Management Steroid Resistant Type 1 Reactions Leprosy</brief_title>
	<detailed_description />
	<mesh_term>Leprosy</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Individuals clinical evidence Type 1 Reaction respond 3 month Prednisolone Treatment Aged 1865 Weigh 30Kg Unwillingness give inform consent Patients severe active infection tuberculosis Pregnant breastfeeding woman ( see Appendix II ) Those renal failure , abnormal renal function , hypertensive Patients take thalidomide currently within last 3 month Patients willing return followup Women reproductive age willing use contraception duration study ( see Appendix II ) HIV positive</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Leprosy</keyword>
	<keyword>Type 1 Reaction</keyword>
	<keyword>Prednisolone</keyword>
	<keyword>Ciclosporin</keyword>
</DOC>